Pills or injections, now that the same drug comes as both

Until recently, choosing an oral GLP-1 meant choosing a different molecule as well as a different route, so nobody could say what the tablet cost you in effect. That changed when the same brand appeared in both forms. Novo now sells Wegovy as a once-weekly subcutaneous injection and as a once-daily tablet, under one label, with one set of approved indications. The comparison below starts there and then widens.

On result, the routes are close

Within the semaglutide pair the numbers are near enough to treat as equivalent: −14% for the tablet against −14.9% for the injection. So the argument for the pill is the route, not a better outcome. Across molecules the picture is different — the largest average result in this class is still an injection, and anyone choosing a tablet over tirzepatide is trading roughly ten percentage points of average trial effect for the absence of a needle. Whether that is a good trade is a real question with a personal answer; it is not a question the marketing usually admits exists.

What the tablet actually asks of you

A weekly injection is an event that happens fifty-two times a year. The Wegovy tablet is a procedure that happens three hundred and sixty-five times a year, and the label sets out the procedure: take it on waking, on an empty stomach, with no more than four ounces of water; swallow it whole, not split, crushed, chewed or dissolved; then wait at least thirty minutes before eating, drinking anything else, or taking any other oral medicine.

That last clause is the one people underestimate. Any other oral medicine includes the morning levothyroxine, the blood-pressure tablet and the contraceptive pill. The label’s own drug-interaction data shows why the rule exists — total thyroxine exposure rose by 33% when levothyroxine was taken alongside oral semaglutide. If your mornings are not reliably yours, the injection is the lower-burden option even though it involves a needle.

Orforglipron does not carry those rules, and this is the substantive reason to care about it. It is an oral small-molecule GLP-1 receptor agonist rather than a peptide protected by an absorption enhancer, so there is no food-and-water window — the tablets are simply swallowed whole. It buys convenience without the daily choreography, at a smaller average effect.

Price, and where the advertised number stops

The orals are being launched into a price war, and the headline figures are titration prices rather than maintenance prices. Novo publishes self-pay pricing of $149 a month for the 1.5 mg and 4 mg Wegovy tablet doses — the first two months of the ladder — and does not publish a self-pay price for the 25 mg maintenance dose on that page. List price is $1,349.02 a package. Lilly publishes orforglipron per dose, from $149 at 0.8 mg to $349 at the top two doses.

So the pattern to watch is the same one that runs through What GLP-1s actually cost in 2026: the advertised price attaches to the dose you are on briefly, and the dose you stay on costs more. Ask what the maintenance dose costs before you judge a programme cheap, and remember that in this class maintenance is the long part — see What happens when you stop.

Switching, if you pick wrong

For Wegovy specifically the label publishes a bridge in both directions. One week after the last 2.4 mg injection you may start 25 mg tablets daily; the day after the last 25 mg tablet you may start 2.4 mg by injection. For someone who could not tolerate the 25 mg tablet, the label suggests the 1.7 mg injection instead. No comparable published bridge exists between molecules, so a switch from tirzepatide to any oral is a fresh titration, not a conversion.